Lorven Biologics Profile
Key Indicators
- Authorised Capital ₹ 4.59 Cr
as on 30-12-2024
- Paid Up Capital ₹ 4.59 Cr
as on 30-12-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.50 Cr
as on 30-12-2024
- Revenue -10.41%
(FY 2022)
- Profit -34.21%
(FY 2022)
- Ebitda 15.41%
(FY 2022)
- Net Worth 39.23%
(FY 2022)
- Total Assets 173.90%
(FY 2022)
About Lorven Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.59 Cr and a paid-up capital of Rs 4.59 Cr.
The company currently has active open charges totaling ₹8.50 Cr.
Venkataramana Mudili, Srikanth Devireddy, and Rahul Peraka serve as directors at the Company.
- CIN/LLPIN
U74120AP2015PTC097532
- Company No.
097532
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Srikakulam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lorven Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkataramana Mudili  | Managing Director | 09-Oct-2015 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srikanth Devireddy | Director | 03-Jul-2023 | Current |
| Rahul Peraka | Director | 01-Mar-2021 | Current |
Financial Performance of Lorven Biologics.
Lorven Biologics Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 10.41% decrease. The company also saw a substantial fall in profitability, with a 34.21% decrease in profit. The company's net worth Soared by an impressive increase of 39.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lorven Biologics?
In 2022, Lorven Biologics had a promoter holding of 97.50% and a public holding of 2.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Srk Cleanrooms Private LimitedActive 3 years 11 months
Venkataramana Mudili and Rahul Peraka are mutual person
Charges (Loans)
₹8.50 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 5.50 Cr
- Sidbi : 3.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2024 | State Bank Of India | ₹5.50 Cr | Open |
| 21 Oct 2021 | Sidbi | ₹2.00 Cr | Open |
| 01 Jul 2021 | Sidbi | ₹1.00 Cr | Open |
How Many Employees Work at Lorven Biologics?
Unlock and access historical data on people associated with Lorven Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lorven Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lorven Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
